H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report) today and set a price target of $85.00. The company’s shares closed last Friday at $35.63, close to its 52-week low of $29.93.
According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.3% and a 37.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Kymera Therapeutics with a $68.29 average price target, an 82.5% upside from current levels. In a report issued on April 9, Brookline Capital Markets also maintained a Buy rating on the stock with a $80.00 price target.
Based on Kymera Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $15.28 million and GAAP net loss of $33.9 million. In comparison, last year the company earned revenue of $12.79 million and had a GAAP net loss of $12.69 million.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KYMR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera’s Pegasus targeted protein degradation platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade the intractable of proteins, and advance new treatment options for patients.
Read More on KYMR:
- KKR Explores Growth Opportunity amid Supply Chain Issues
- H.C. Wainwright Remains a Buy on Blueprint Medicines (BPMC)
- Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY), Stealth Biotherapeutics (MITO) and Genocea Biosciences (GNCA)
- Novavax Receives Authorization to Inject COVID-19 Vaccine in Thailand
- Berenberg Bank Thinks Nurix Therapeutics’ Stock is Going to Recover